BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib. [electronic resource]
Producer: 20190724Description: e10-e12 p. digitalISSN:- 1592-8721
- Alleles
- Amino Acid Substitution
- Antineoplastic Agents -- pharmacology
- Dose-Response Relationship, Drug
- Drug Resistance, Neoplasm -- genetics
- Fusion Proteins, bcr-abl -- genetics
- Gene Expression
- Humans
- Imidazoles -- pharmacology
- Mutation
- Pharmacogenomic Testing
- Pharmacogenomic Variants
- Protein Kinase Inhibitors -- pharmacology
- Pyridazines -- pharmacology
No physical items for this record
Publication Type: Letter; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.